Q-omics provides the consensus-scored TXNDC11 profile across patient tissues and cancer cell-line models. TXNDC11 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TXNDC11 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TXNDC11 protein abundance shows 19,248 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, KIRC, and PDAC as cancer lineages where TXNDC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNDC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNDC11 survival associations across molecular data types. TXNDC11 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNDC11 RNA expression–survival associations across cancer types. High TXNDC11 expression shows favorable associations in SKCM, LUAD, KIRC, UCEC, HNSC and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TXNDC11 RNA expression.
This table summarizes TXNDC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TXNDC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNDC11 shows lower tumor expression in COAD, THCA and LUSC and higher tumor expression in KIRC, HNSC and BRCA. The KIRC box plot shows higher TXNDC11 RNA expression in tumor versus normal tissue (log2 FC = +0.669, t-test p < 0.001).
This table shows molecular features associated with TXNDC11 in patient tissues and cancer cell lines. In patient samples, TXNDC11 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNDC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
